Category list : Scottish Medicines Consortium
Sort by: Newest first Oldest first A-Z Z-A
-
Siponimod now recommended for patients with secondary progressive MS Subscription
Updated draft guidance from the National Institute for Health and Care Excellence has recommended siponimod for the treatment of secondary progressive multiple sclerosis.
-
Scottish Medicines Consortium accepts nasal spray for depression previously rejected by NICE Subscription
The Scottish Medicines Consortium has accepted the use of esketamine nasal spray for use within NHS Scotland for adults with treatment-resistant major depressive disorder.
-
Cannabis-based Epidyolex approved for NHS use in Scotland Subscription
Epidyolex, a cannabidiol medicine for severe epilepsy in children, has been approved for use on the NHS in Scotland.
-
Biologic injection for severe asthma approved in Scotland
A biologic injection intended for the treatment of severe eosinophilic asthma has been accepted for restricted use by the Scottish Medicines Consortium, providing another option for patients who fail to respond to other treatments.
-
Daratumumab recommended for treatment of multiple myeloma in Scotland
The Scottish Medicines Consortium (SMC) has recommended daratumumab (Darzalex) for use as a fourth-line treatment option in multiple myeloma.
-
Scotland will fund pre-exposure prophylaxis for people at high risk of HIV
People in Scotland at risk of HIV will be able to access pre-exposure prophylaxis (PrEP) treatment on the NHS.
-
Breast cancer drug deemed too expensive in England has been approved in Scotland
NHS Scotland has approved the use of breast cancer drug Kadcyla, which was rejected for use in England on the grounds that its benefits did not justify its cost.
-
Cancer charities say patients are being denied access to new drugs
NHS cancer patients are missing out on innovative new drugs which are available in other European countries because of a flawed assessment and pricing system, according to a report published by cancer charities Breast Cancer Now and Prostate Cancer UK.
-
February 2016: SMC decisions Subscription
The Scottish Medicines Consortium has approved the following medicines for use in NHS Scotland for specific indications: fulvestrant (Faslodex; AstraZeneca); golimumab (Simponi; Merck Sharp and Dohme); guanfacine (Intuniv; Shire); panobinostat (Farydak; Novartis); and ulipristal acetate (Esmya; Gedeon Richter). Eculizumab (Soliris; Alexion), pixantrone (Pixuvri; CTI Life Sciences) and teduglutide (Revestive; NPS Pharma) have not been recommended for use.
-
Scottish government announces review of how medicines are assessed for NHS use Subscription
The Scottish government has announced an independent review into the way that new drugs are assessed for use in the NHS that will report back to ministers by summer 2016.
Show 10 per page20 per page50 per page
